SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide $(PEA.AU)$. This innovative combination is designed to enhance pain and fever relief with lower doses and fewer side effects compared to paracetamol alone. By potentially offering a safer and more effective treatment option, the drug candidate aims to minimize risks like liver damage while improving outcomes for various types of pain and fever, marking a significant advancement in pain management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.